Zekauskas stated, “We do not believe that the split announcement has lowered the value of Corteva. We think that the sharp decrease in the value of Corteva has created an undervaluation of the company.” He maintained a year-end target of $70, suggesting a potential upside of approximately 14% from Wednesday’s closing price of $61.47. In premarket trading, the stock showed little change.
Despite being a laggard this year, with a rise of nearly 8%, Corteva’s performance pales in comparison to the S&P 500, which has increased by over 14%. However, Zekauskas believes that Corteva’s strategy to enhance value through the spinoff of its seed and crop chemical divisions could prove beneficial. He noted that the crop chemicals segment might command a higher trading multiple.
“When we look at the valuation of the two pieces of Corteva, we think that the Seed company is currently selling at about 13.5x EBITDA, with a gross margin exceeding 50%. In contrast, the Crop Chemical company is trading at 6x EBITDA based on 2025 estimates,” Zekauskas explained. He further elaborated that the Seed company is valued at approximately 13.5x EBITDA, while the Crop Chemical company is projected to trade at 4x EBITDA based on forecasts for 2026.
Zekauskas added, “We believe that a more typical trading multiple for Corteva’s crop chemical EBITDA would be closer to 9x-10x or at a premium to FMC.” This perspective highlights the potential for growth and value creation within Corteva’s business model, especially as it navigates the upcoming changes.
(Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here.)
